The Joe Tippens protocol is an unofficial cancer treatment regimen centered on fenbendazole, an antiparasitic drug designed for animals, combined with several over-the-counter supplements. It gained widespread attention after Joe Tippens, a man diagnosed with stage IV small cell lung cancer in 2016, publicly claimed that adding fenbendazole to his treatment led to his tumors shrinking and eventually being declared cancer-free. No clinical trial has tested this protocol in humans, and fenbendazole is not approved for human use by either the FDA or the European Medicines Agency.
How the Protocol Started
Joe Tippens was diagnosed with stage IV small cell lung cancer, a form of the disease with notoriously low survival rates. He has said that a veterinarian suggested he try fenbendazole, a common deworming medication used in dogs and other animals. Tippens reported that after several months of taking fenbendazole alongside his conventional cancer treatment, his scans showed remarkable tumor regression, and he was eventually declared cancer-free.
Tippens shared his story on a blog and through media appearances, and it spread rapidly online. His account resonated particularly strongly in South Korea, where surveys found significant numbers of cancer patients self-administering veterinary antiparasitic drugs based on his story. It’s important to note that Tippens was also receiving conventional cancer treatment during this period, making it impossible to attribute his outcome to fenbendazole alone.
What the Protocol Includes
As documented in a peer-reviewed survey published in PLOS One, the regimen Tippens used consisted of three components taken daily plus fenbendazole on a cycling schedule:
- Fenbendazole: 222 mg per day, taken for 3 consecutive days followed by 4 days off
- Curcumin: 600 mg per day
- Cannabidiol (CBD) oil: 25 mg per day
Some versions of the protocol circulating online also include vitamin E, though the peer-reviewed documentation of the original regimen lists only these three components. People who follow this protocol typically purchase fenbendazole as Panacur or Safe-Guard, both veterinary products sold for deworming dogs.
Why Fenbendazole Gets Attention in Cancer Research
Fenbendazole belongs to a family of drugs called benzimidazoles. In lab studies, it has shown the ability to kill cancer cells through several mechanisms working simultaneously. A 2018 study published in Scientific Reports found that fenbendazole disrupts the internal scaffolding of cancer cells (structures called microtubules that cells need to divide), stabilizes a key tumor-suppressing protein called p53, and interferes with how cancer cells absorb and process sugar for energy.
That last mechanism is particularly interesting. Cancer cells are notorious for their heavy reliance on glucose. Fenbendazole appears to reduce their ability to take in glucose by lowering the number of sugar transporters on the cell surface and blocking a critical enzyme involved in sugar metabolism. In lab dishes, this combination of effects killed human cancer cells at relatively low concentrations.
These findings are genuine, but they come with a major caveat: killing cancer cells in a dish is far easier than treating cancer in a living person. Thousands of compounds show anticancer activity in lab settings and never work in human trials. The jump from “this kills cancer cells in vitro” to “this treats cancer in patients” is one of the largest gaps in medicine.
Mebendazole: The Human-Approved Relative
Fenbendazole has a close chemical cousin called mebendazole that is already approved for human use as an antiparasitic. In lab comparisons, the two drugs show nearly identical potency against cancer cells, with similar concentrations needed to inhibit cell growth. But mebendazole has a dramatically larger safety record: its safety has been evaluated in over 6,200 subjects across 39 clinical trials, plus decades of post-marketing data.
At least six clinical trials have investigated or are investigating mebendazole as a potential cancer treatment, and two published case reports describe its use in patients with metastatic cancer. Some researchers and oncologists have pointed out that if patients are interested in this drug class, mebendazole would be the more logical choice because it has established human dosing, known drug interactions, and a documented safety profile. Fenbendazole, by contrast, is approved only for veterinary use, and researchers have noted that the literature on repurposing it for cancer is more limited.
Safety Risks of Fenbendazole in Humans
Because fenbendazole was never designed for human consumption, there is no established safe dosage for people. Case reports of harm are beginning to appear in the medical literature. The most striking is a 67-year-old woman who developed severe liver injury after self-administering fenbendazole for a precancerous skin lesion. She had been taking three 1-gram packets of fenbendazole granules three times per week for about a year, a dose considerably higher than what the Tippens protocol calls for.
Her liver enzymes climbed to extreme levels, and her bilirubin (a marker of liver damage) peaked at 24 mg/dL, roughly 20 times the normal upper limit. A liver biopsy confirmed widespread cell death in the liver tissue. This was the first histologically confirmed case of severe drug-induced liver injury from fenbendazole. Her liver function did normalize about three months after she stopped taking the drug, but the case illustrates that fenbendazole is not harmless simply because it is available without a prescription.
At least one additional, milder case of liver injury has been reported in a woman with lung cancer, though that case had a possible complicating factor from her immunotherapy treatment.
Absorption and How People Take It
Studies in dogs show that fenbendazole is absorbed significantly better when taken with food compared to taking it on an empty stomach. The fat content of the meal didn’t make a meaningful difference in absorption levels; what mattered was simply having food present. People following the protocol typically take fenbendazole with a meal for this reason, though again, no human pharmacokinetic studies have established optimal dosing conditions for people.
What the Evidence Actually Shows
No controlled clinical trial has tested the Joe Tippens protocol or fenbendazole as a cancer treatment in humans. The evidence that exists is limited to lab studies, animal experiments, and a small number of individual case reports. A 2025 case series examining three patients who self-administered fenbendazole noted that while the cases offered a “compelling rationale” for further investigation, the data was observational and lacked the methodological rigor of a clinical trial. The authors called for controlled trials, regulatory guidance, and better education around repurposed drugs in oncology.
The core problem with Joe Tippens’ story, compelling as it is, is that a single person’s recovery while also receiving conventional treatment cannot prove that fenbendazole was responsible. Spontaneous regressions, delayed responses to chemotherapy, and other variables make individual cases unreliable as evidence. Until controlled trials compare fenbendazole (or mebendazole) against standard care in matched groups of patients, there is no way to know whether these drugs meaningfully help people with cancer, at what doses, or for which cancer types.